2,4,6-Tribromoanisole and 2,4,6-Trichloroanisole - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

2,4,6-Tribromoanisole and 2,4,6-Trichloroanisole
A review of taints and odors in the pharmaceutical and consumer healthcare industries.

Pharmaceutical Technology
Volume 36, Issue 9, pp. 56-62


1. PDA, "Technical Report No. 55: Detection and Mitigation of 2,4,6-Tribromoanisole and 2,4,6-Trichloroanisole Taints and Odors in the Pharmaceutical and Consumer Healthcare Industries," (April 2012), available at http://store.pda.org/ProductCatalog/Product.aspx?ID=1549.

2. Anon, "Organohalogen Taints in Foods," Australian Food and Grocery Council Supplement to Food Australia, 59 (3), (2007), http://www.afgc.org.au/cmsDocuments/Organohalogen.pdf

3. PDA, "Risk Mitigation of Tribromoanisole (TBA)/Trichloroanisole (TCA) Taints and Odors: A Pharmaceutical Industry Benchmarking Survey" (2011), available at http://store.pda.org/bookstore/ProductDetails.aspx?productabbreviation=45000.

4. FDA, "Questions and Answers on Current Good Manufacturing Practices, Good Guidance Practices, Level 2 Guidance–Buildings and Facilities" (FDA, Rockville, MD), http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm192869.htm.

5. T. Ramstad and J.S.Walker, Analyst 117 (8), 1361–1366 (1992).

6. R.J. Bleiler, F. Kuhrt, and D. Wright, Analytical Technology and Laboratory Testing, supp. to Pharm. Technol. 35 (11) s10-14 (2011).

7. F. Koshier et al., Food Chem. Toxicol. 49 (9), 2074–2080 (2011).

8. ICH, Q9 Quality Risk Management (2005).

9. ISO 13299:2003, Sensory Analysis-General Guidance for the Design of Test Rooms.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here